Clinical implications of HIV and hepatitis B co-infection in Asia and Africa

Research output: Contribution to journalReview articlepeer-review

Abstract

Hepatitis B virus (HBV) is the leading cause of chronic liver disease and liver-related death worldwide, with the majority of these cases occurring in areas of Africa and Asia where HBV prevalence is high. Many of the countries that are affected by hepatitis B are also affected by a high HIV burden, leading to frequent HIV/HBV co-infection. The consequences of co-infection, including increased liver-related morbidity and mortality, increased hepatitis B viral replication, immune reconstitution to HBV in the setting of antiretroviral therapy, and hepatotoxicity from antiretroviral drugs, are especially important in regions with expanding antiretroviral programmes. Little data, however, are available on HIV/HBV co-infection from regions with high chronic hepatitis B prevalence. This Review discusses the epidemiology, natural history, pathogenesis, and management of HIV/HBV co-infection from these areas. Topics for future research relevant to HIV/HBV co-infection in Africa and Asia are also highlighted.

Original languageEnglish (US)
Pages (from-to)402-409
Number of pages8
JournalLancet Infectious Diseases
Volume7
Issue number6
DOIs
StatePublished - Jun 1 2007

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'Clinical implications of HIV and hepatitis B co-infection in Asia and Africa'. Together they form a unique fingerprint.

Cite this